Renato Costa

A short 7-2 ruling by the U.S. Supreme Court Friday evening ordered the abortion drug mifepristone may remain on the market until a federal lower court rules on the matter, giving the Joe Biden regime a temporary win pending a court determination.

“In this case, the issue is not abortion pills directly, but whether the FDA acted appropriately in approving the drug more than 20 years ago. The Alliance Defending Freedom, which represents the pro-life plaintiffs, alleges the FDA ‘chose politics over science’ in approving the drug and acted unlawfully by removing safeguards around mifepristone, including permitting the pill to be delivered by mail,” reported Fox News. 

In a dissenting opinion, Justice Samuel A. Alito, Jr. wrote, “ At present, the applicants are not entitled to a stay because they have not shown that they are likely to suffer irreparable harm in the interim. The applicants claim that regulatory “chaos” would occur due to an alleged conflict between the relief awarded in these cases and the relief provided by a decision of the United States District Court for the Eastern District of Washington. It is not clear that there actually is a conflict because the relief in these cases is a stay, not an injunction, but even if there is a conflict, that should not be given any weight. Our granting of a stay of a lower-court decision is an equitable remedy.”

He further noted, “The Food and Drug Administration (FDA) has engaged in what has become the practice of ‘leverag[ing]’ district court injunctions “as a basis’ for implementing a desired policy while evading both necessary agency procedures and judicial review.” 

Justices Alito and Clarence Thomas were the only justices to dissent from the majority opinion, with no other justice weighing in on the matter. 

The Supreme Court’s ruling on the matter followed U.S. District Judge Matthew J. Kacsmaryk’s ruling on a case ordering the abortion drug to be banned from being distributed due to the unsafe nature of its contents, which has been proven in the case.

A 2021 scientific study found from FDA data between 2000 and 2019 that there were many deaths and adverse medical events directly linked to the use of mifepristone. The researchers found in their research that “[s]ignificant morbidity and mortality have occurred following the use of mifepristone as an abortifacient.”

Until the Fifth Circuit rules on the case, the abortion drug will be allowed to be disseminated. Some radical far-left pro-abortion sources are claiming they will create a black market for the killing drug even if a court strikes it down, opening the possibility for more women to be maimed and killed by the abortion industry via contraband efforts.